LONDON, ON, June 19, 2013 /CNW/ - A Settlement Agreement in the Canada wide Neurontin class action has now been approved by the Ontario Superior Court of Justice. The class action was previously certified on behalf of Canadians who were prescribed and ingested the drug Neurontin prior to August 5, 2004 in respect of allegations that use of Neurontin, a prescription anticonvulsant commonly prescribed for off-label uses, results in an increased risk of experiencing suicidal behaviour.
"We are very pleased with this result and look forward to moving ahead with the implementation of the compensation program" says Matt Baer, one of the Class Counsel responsible for negotiating the settlement. "We would like to commend the Defendants for putting this compensation program in place for Canadians even though they deny any liability and this settlement is not an admission of any liability." "Formal notice of the settlement is being disseminated which provides details, including deadlines, of how claimants are able to submit a claim."
SOURCE: Siskinds LLP
For further information:
Please see www.classaction.ca/neurontin (English and French), or contact Matt Baer (English enquiries) at (519) 660-7782 or Ursula Anzigbamo (French enquiries) at (519) 672-2121 ext 2409.